POMT1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Finally, the question remains whether our data could provide structural and functional explanations for mutations in the human POMT1/2 homologs that cause α-dystroglycanopathies (reviewed in Endo, 2015).